TY - JOUR T1 - One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis JF - British Journal of Ophthalmology JO - Br J Ophthalmol DO - 10.1136/bjophthalmol-2021-320631 SP - bjophthalmol-2021-320631 AU - Alexander Tanner AU - Fadi Haddad AU - Julia Fajardo-Sanchez AU - Ethan Nguyen AU - Kai Xin Thong AU - Sarah Ah-Moye AU - Nicole Perl AU - Mohammed Abu-Bakra AU - Avinash Kulkarni AU - Sameer Trikha AU - Gerassimos Lascaratos AU - Miles Parnell AU - Obeda Kailani AU - Anthony J King AU - Pavi Agrawal AU - Richard Stead AU - Konstantinos Giannouladis AU - Ian Rodrigues AU - Saurabh Goyal AU - Pirro G Hysi AU - Sheng Lim AU - Cynthia Yu-Wai-Man Y1 - 2022/03/31 UR - http://bjo.bmj.com/content/early/2022/03/31/bjophthalmol-2021-320631.abstract N2 - Background/aims To evaluate the efficacy and safety of the PreserFlo MicroShunt glaucoma device in a multicentre cohort study.Methods All consecutive patients who received the microshunt with mitomycin-C (MMC) 0.4 mg/mL from May 2019 to September 2020 in three UK tertiary centres. Primary outcome at 1 year was a complete success, with failure defined as intraocular pressure (IOP) >21 mmHg or <20% reduction, IOP≤5 mmHg with any decreased vision on two consecutive visits, reoperation or loss of light perception vision. Secondary outcomes were IOP, best-corrected visual acuity, medications, complications, interventions and reoperations. We also performed subgroup analyses for severe glaucoma and assessed risk factors for failure.Results 104 eyes had 1-year follow-up. Complete and qualified success at 1 year were achieved in 51.9% (N=54) and 16.4% (N=17), respectively, and failure occurred in 31.7% (N=33). There was a significant reduction in IOP (mmHg) from preoperatively (23.4±0.8, N=104) to 12 months (14.7±0.6, N=104) (p<0.0001). Antiglaucoma medications also decreased from preoperatively (3.4±0.1, N=104) to 12 months (0.7±0.1, N=104) (p<0.0001). Multivariate analyses showed an association between higher mean deviation and failure (HR 1.055, 95% CI 1.0075 to 1.11, p=0.0227). Complications were hypotony (19.2%; N=20), choroidal detachments (10.6%; N=11), hyphaema (5.8%; N=6) and bleb leak (5.8%; N=6). Needling and 5-fluorouracil injections were performed in 12.5% (N=13) and 33.7% (N=35), respectively, and 11.5% (N=12) required revision surgery.Conclusion The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.All data relevant to the study are included in the article or uploaded as online supplemental information. Not applicable. ER -